Skip Navigation


Journal of Public Health Advance Access originally published online on March 14, 2009
Journal of Public Health 2009 31(3):434-445; doi:10.1093/pubmed/fdp024
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
31/3/434    most recent
fdp024v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chilet-Rosell, E.
Right arrow Articles by Horga, J. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chilet-Rosell, E.
Right arrow Articles by Horga, J. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009, Published by Oxford University Press on behalf of Faculty of Public Health. All rights reserved

Women's health and gender-based clinical trials on etoricoxib: methodological gender bias



E. Chilet-Rosell, Research Assistant1

M. T. Ruiz-Cantero, Professor of Public Health1,2

J. F. Horga, Professor of Pharmacology3
1 Preventive Medicine and Public Health Unit, University of Alicante, PO Box 99, 03080 Alicante, Spain
2 Epidemiology and Public Health, Centre of the Biomedical Research Network (CIBERESP), Spanish Ministry of Health, Alicante, Spain
3 Clinical Pharmacology Unit, Hospital General Universitario de Alicante, Alicante, Spain

Address correspondence to Elisa Chilet-Rosell, E-mail: elisa.chilet{at}ua.es


  Abstract

Background The aim of this study was to determine compliance with published good practice guidelines for gender and clinical trials using etoricoxib. The rationale for choosing etoricoxib was that it is widely used by women and there is evidence of potential interaction with contraceptives and hormone replacement therapy as highlighted in the product characteristics.

Methods The study reviewed 58 etoricoxib published trials (54 papers) to determine if they met the gender recommendations of the Guidelines of Food and Drug Administration (1993) and the Sex, Gender and Pain Special Interest Group Consensus Working Group Report (2007).

Results Women formed 70% of a total of 49 835 subjects included in the etoricoxib trials, but only 31% of the subjects were in Phase I. About 85.7% of trials did not show sex-stratified data. About 90.6 and 93.3% did not provide efficacy and adverse effects data by sex, respectively. There is scarce information about the influence of issues that specifically affect women.

Discussion Women are under-represented in the published etoricoxib trials, specifically, in Phase I. Sex-stratified data on efficacy and adverse effects are scarce in etoricoxib trials. Together with the lack of data on women-specific issues, this suggests that etoricoxib may pose the same potential problems for women as other cyclooxygenase-2 inhibitors.

Keywords: clinical trials, etoricoxib, gender bias, gender differences, sex differences


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.